Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 3, 2002 - Issue 8
Submit an article Journal homepage
59
Views
7
CrossRef citations to date
0
Altmetric
Miscellaneous

Pharmacotherapy of Candida bloodstream infections: new treatment options, new era

Russell E Lewis Assistant Professor, University of Houston College of Pharmacy, 1441 Moursund St. #423, Texas Medical Center, Houston, TX 77030, USA, Tel: +1 713 795 8326; Fax: +1 713 795 8383;, E-mail: [email protected]
Pages 1039-1057 | Published online: 25 Feb 2005

Bibliography

  • EDMOND MB, WALLACE SE, MCCLISH DK, PFALLER MA, JONES RN, WENZEL RP: Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Gin. Infect. Dis. (1999) 29(2):239–244.
  • PFALLER MA, DIEKEMA DJ, JONES RN et al.: International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J. Clin. Microbial. (2001) 39(9):3254–3259.
  • PFALLER MA, JONES RN, DOERN GV et al.: Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1. Antimicrob. Agents Chemother. (2000) 44(3):747–751.
  • PFALLER MA: Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Gin. Infect. Dis. (1996) 22\(Suppl. 2):589–594.
  • NATIONAL CANCER TREATMENT NETWORK: NCCN practice guidelines for fever and neutropenia. Oncology (1999) 13(5A):197–257.
  • REX JH, BENNETT JE, SUGAR AM et al.: A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl. I Med. (1994) 331(20):1325–1330.
  • •Seminal paper.
  • PHILLIPS P, SHAFRAN S, GARBER G et al.: Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group. Eur. I Clin. Microbial. Infect. Dis. (1997) 16(5):337–345.
  • •Seminal paper.
  • ANAISSIE EJ, DAROUICHE RO, ABI-SAID D et al.: Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin. Infect. Dis. (1996) 23(5):964–972.
  • NGUYEN MH, PEACOCK JE Jr, TANNER DC et al.: Therapeutic approaches in patients with candidemia. Evaluation in a multicenter, prospective, observational study. Arch. Intern. Med. (1995) 155(22):2429–2435.
  • SLAVIN MA, OSBORNE B, ADAMS R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. I Infect. Dis. (1995) 171(6):1545–1552.
  • GOODMAN JL, WINSTON DJ, GREENFIELD RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl. I Med. (1992) 326(13) :845–851.
  • •Seminal paper.
  • PELZ RK, HENDRIX CW, SWOBODA SM et al.: Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann. Surg. (2001) 233(4):542–548.
  • •Seminal paper.
  • REX JH, SOBEL JD: Prophylactic antifungal therapy in the intensive care unit. Gin. Infect. Dis. (2001) 32(8):1191–1200.
  • ••Excellent review.
  • EGGIMANN P, FRANCIOLI P, BILLE J et al.: Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit. Care Med. (1999) 27(6):1066–1072.
  • BOHME A, KARTHAUS M, HOELZER D: Antifungal prophylaxis in neutropenic patients with hematologic malignancies. Antibior Chemother. (2000) 50:69–78.
  • GOTZSCHE PC, JOHANSEN HK: Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. Br. Med. (1997) 314(7089):1238–1244.
  • REX JH, WALSH TJ, SOBEL JD et al: Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis. (2000) 30(4):662–678.
  • ABI-SAID D, ANAISSIE E, UZUN O, RAAD I, PINZCOWSKI H, VARTIVARIAN S: The epidemiology of
  • •• hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. (1997) 24(6):1122–1128.
  • ROCCO TR, REINERT SE, SIMMS HH: Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance. Arch. &mg. (2000) 135(2):160–165.
  • MCNEIL MM, NASH SL, HAJJEH RA et al.: Trends in mortality due to invasive mycotic diseases in the United States, 1980-1. Clin. Infect. Dis. (2001) 33(5):641–647.
  • LIN S, SCHRANZ J, TEUTSCH S: Aspergillosis case-fatality rate: systematic review of the literature. Clin. Infect. Dis. (2001) 32(3):358–366.
  • VAN BURIK JH, LEISENRING W, MYERSON D et al.: The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) (1998) 77(4):246–254.
  • HOSSAIN MA, GHANNOUM MA: New investigational antifungal agents for treating invasive fungal infections. Expert. Opin. Investig. Drugs (2000) 9(8):1797–1813.
  • PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN, DIEKEMA DJ: ha vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. (2002) 46(6):1723–1727.
  • PFALLER MA, MESSER SA, HOLLIS RJ, JONES RN: Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2. Antimicrob. Agents Chemother: (2002) 46(4):1032–1037.
  • PFALLER MA, DIEKEMA DJ, JONES RN, MESSER SA, HOLLIS RJ: Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. J Clin Microbial (2002) 40(3):852–856.
  • GROLL AH, PISCITELLI SC, WALSH TJ: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol (1998) 44:343–500.
  • ••The most comprehensive review ofantifungal pharmacology in print.
  • ••REX JH, PFALLER MA, WALSH TJ et al.: Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbial. Rev (2001) 14(4):643–658.
  • SANGLARD D, ODDS FC: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect. Dis. (2002) 2(2):73–85.
  • ”KONTOYIANNIS DP, LEWIS RE: Antifungal drug resistance of pathogenic fungi. Lancet (2002) 359(9312):1135–1144.
  • FRANCIS P, WALSH TJ: Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin. Infect. Dis. (1992) 15(6):1003–1018.
  • LEWIS RE, KONTOYIANNIS DP: Rationale for combination antifungal therapy. Pharmacotherapy (2001) 21(8, Part 2):1495–1645.
  • POIRIER JM, CHEYMOL G: Optimisation of itraconazole therapy using target drug concentrations. Clin. Pharmacokinet. (1998) 35(6):461–473.
  • DE BEULE K, VAN GESTEL J: Pharmacology of itraconazole. Drugs (2001) 61\(Suppl. 1):27–37.
  • REX JH, WALSH TJ, ANAISSIE EJ: Fungal infections in iatrogenically compromised hosts. Adv. Intern. Med. (1998) 43:321–371.
  • REX JH, PFALLER MA, GALGIANI JN et al.: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. (1997) 24 (2):235–247.
  • GRANINGER W, PRESTERIL E, SCHNEEWEISS B, TELEKY B, GEORGOPOULOS A: Treatment of Candida albicans fungaemia with fluconazole. Infect. (1993) 26(2):133–146.
  • DUSWALD KH, PENK A, PITTROW L: High-dose therapy with fluconazole or = 800 mg day. Mycoses (1997) 40(7-8):267–277.
  • MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients; a multicentre, randomized, double blind study. 12th European Congress of Clinical Microbiology and Infectious Diseases. Milan, Italy (24–27 April 2002).
  • ALEXANDER BD, PERFECT JR: Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs (1997) 54(5):657–78.
  • MARR KA, LYONS CN, HA K, RUSTAD TR,WHITE TC: Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother: (2001) 45(1):52–59.
  • YOON SA, VAZQUEZ JA, STEFFAN PE, SOBEL JD, AKINS RA: High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance. Antimicrob. Agents Chemother. (1999) 43(4):836–845.
  • BODEY GP, ANAISSIE E, EDWARDS JE. Definitions of Candida infections. In: Candidiasis: Pathogenesis, Diagnosis, and Treatment. Bodey GP (Ed.), Raven Press, New York, USA (1993):407–408.
  • BODEY GP, LUNA MA: Disseminated candidiasis in patients with acute leukemia: two diseases? Clin. Infect. Dis. (1998) 27(1):238.
  • FRASER VJ, JONES M, DUNKEL J, STORFER S, MEDOFF G, DUNAGAN WC: Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality. Clin. Infect. Dis. (1992) 15(3):414–421.
  • KONTOYIANNIS DP, LUNA MA, SAMUELS BI, BODEY GP: Hepatosplenic candidiasis. A manifestation of chronic disseminated candidiasis. Infect. Dis. Clin. North Am. (2000) 14 (3):721–739.
  • CHRISTIANSEN KJ, BERNARD EM, GOLD JVV, ARMSTRONG D: Distribution and activity of amphotericin B in humans. I Infect. Dis. (1985) 152(5):1037–1043.
  • EDWARDS JE Jr, BODEY GP, BOWDEN RA et al.: International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. (1997) 25(1):43–59.
  • SALLAH S, SEMELKA RC, SALLAH W, VAINRIGHT JRPHILIPS DL: Amphotericin B lipid complex for the treatment of patients with acute leukemia and hepatosplenic candidiasis. Leak. Res. (1999) 23(11):995–999.
  • COLLETTE N, VAN DER AUWERA P, LOPEZ AP, HEYMANS C, MEUNIER F: Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B deoxycholate. Antimicrob. Agents Chemother. (1989) 33(3):362–368.
  • OLDFIELD EC, GARST PD, HOSTETTLER C, WHITE M, SAMUELSON D: Randomized, double-blind trial of 1- versus 4-hour amphotericin B infusion durations. Antimicrob. Agents Chemother. (1990) 34(7):1402–1406.
  • OLDFIELD EC: Meperidine for prevention of amphotericin B-induced chills. Clin. Pharm. (1990) 9(4):251–252.
  • SABRA R, BRANCH RA: Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob. Agents Chemother. (1991) 35(12):2509–2014.
  • WINGARD JR, KUBILIS P, LEE Let al.: Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect Dis. (1999) 29(6):1402–1407.
  • ZAGER RA, O'QUIGLEY J, ZAGER BK et al.: Acute renal failure following bone marrow transplantation: a retrospective study of 272 patients. Am. Kidney Dis. (1989) 13(3):210–216.
  • HEIDEMANN H: Prevention of amphotericin B nephrotoxicity: the effect of salt loading and flucytosine. Mykosen Stipp]. (1988) 2:39–44.
  • GARDNER ML, GODLEY PJ, WASAN SM: Sodium loading treatment for amphotericin B-induced nephrotoxicity. DICP (1990) 24(10):940–946.
  • BRANCH RA: Prevention of amphotericin B-induced renal impairment. A review on the use of sodium supplementation. Arch. Intern. Med. (1988) 148(11):2389–2394.
  • SHEEHAN DJ, HITCHCOCK CA, SIBLEY CM: Current and emerging azole antifungal agents. Clin. Microbial. Rev (1999) 12(1):40–79.
  • GUBBINS PO, MCCONNELL SAPENZAK SR: Antifungal agents. In: Drug Interactions in Infectious Disease. Piscetelli SC, Rodvold KA (Eds), Human Press, Totowa, NJ, USA (2001):185–217
  • NICOLAU DP, CROWE HM, NIGHTINGALE CH, QUINTILIANI R: Rifampin-fluconazole interaction in critically ill patients. Ann. Pharmacother: (1995) 29(10):994–996.
  • GROLL AH, WALSH TJ: Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin. Investig. Drugs (2001) 10(8):1545–1558.
  • ARATHOON EG: Clinical efficacy of echinocandin antifungals. Curt: Opin. Infect. Dis. (2001) 14(6):685–691.
  • ARATHOON EG, GOTUZZO E, NORIEGA LM, BERMAN RS, DINUBILE MJ, SABLE CA: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother: (2002) 46(2):451–457.
  • CENTER FOR DRUG EVALUATION AND RESEARCH: Caspofungin - background document for the antiviral drug products advisory committee meeting - Cancidas (caspofungin acetate for intravenous injection); NDA 21-Vol. 2001: FDA Center for Drug Evaluation and Research (2001).
  • •See [201].
  • HIEMENZ JW, WALSH TJ: Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. (1996) 22\(Suppl. 2):5133–5144.
  • WALSH TJ, GOODMAN JL, PAPPAS P et al.: Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob. Agents Chemother. (2001) 45(12):3487–3496.
  • WONG-BERINGER A, JACOBS RA, GUGLIELMO BJ: Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. (1998) 27(3):603–618.
  • WINGARD JR, WHITE MH, ANAISSIE E, RAFFALLIJ, GOODMAN J, ARRIETA A: A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin. Infect. Dis. (2000) 31(5):1155–1163.
  • DERAY G: Amphotericin B nephrotoxicity. .1. Antimicrob. Chemother: (2002) 49\(Suppl. 1):37–41.
  • ROLAND WE: Amphotericin B colloidal dispersion versus amphotericin B in the empirical treatment of fever and neutropenia. Clin. Infect. Dis. (1999) 28(4):935–936.
  • REX JH, WALSH TJ, NETTLEMAN Met al.: Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin. Infect. Dis. (2001) 33(1):95–106.
  • ERIKSSON U, SEIFERT B, SCHAFFNER A: Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ(2001) 322(7286):579–582.
  • DENNING DW, LEE JY, HOSTETLER JS et al: NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am..! Med. (1994) 97(2):135–144.
  • •Seminal trial.
  • GLASMACHER A, MOLITOR E, MEZGER JMARKLEIN G: Antifungal prophylaxis with itraconazole in neutropenic patients: pharmacological, microbiological and clinical aspects. Mycoses (1996) 39(7-8):249–258.
  • BOOGAERTS MA, VERHOEF GE, ZACHEE P, DEMUYNCK H, VERBIST LDE BEULE K: Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses (1989) 32\(Suppl. 1):103–108.
  • LANGE D, PAVAO JH, WU JK, LAUSNER M: Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers.J. Clin. Pharmacol (1997) 37(6):535–540.
  • HEYKANTS J, VAN PEER A, VAN DE VELDE V et al.: The clinical pharmaco-kinetics of itraconazole: an overview. Mycoses (1989) 32\(Suppl. 1):67–87.
  • MASCARENAS CA, HARDIN TC, PENNICK GJ, RINALDI MG, GRAYBILL JR: Treatment of thrush with itraconazole solution: evidence for topical effect. Clin. Infect. Dis. (1998) 26(5):1242–1243.
  • STEVENS DA: Itraconazole in cyclodextrinsolution. Pharmacotherapy (1999) 19(5):603–611.
  • BOOGAERTS MA, MAERTENS J, VAN DER GEEST R et al.: Pharmacokinetics and safety of a 7-day administration of intravenous itraconazole followed by a 14-day administration of itraconazole oral solution in patients with hematologic amalignancy. Antimicrob. Agents. Chemother. (2001) 45(3):981–985.
  • 81300 GAERTS M, WINSTON DJ, BOW EJ et al.: Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann. Intern. Med. (2001) 135(6):412–422.
  • GLASMACHER A, HAHN C, MOLITOR E, MARKLEIN G, SAUERBRUCH T, SCHMIDT-WOLF IG: Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses (1999) 42(11-12):591–600.
  • AHMAD SR, SINGER SJ, LEISSA BG: Congestive heart failure associated with itraconazole. Lancet (2001) 357(9270):1766–1767.
  • NEELY MN, GHANNOUM MA: The exciting future of antifungal therapy. Eur. Clin. Microbiol Infect. Dis. (2000) 19(12):897–914.
  • CENTER FOR DRUG EVALUATION AND RESEARCH: Voriconazole - back-ground document for the Antiviral Drug Products Advisory Committee - voricon-azole tablets and voriconazle injection; NDAs 21–266 and 21–267: FDA Center for Drug Evaluation and Research, 2.
  • •See [201].
  • WALSH TJ, PAPPAS P, WINSTON DJ et al.: Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl. Med. (2002) 346(4):225–234.
  • DENNING DW, RIBAUD P, MILPIED N et al.: Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin. Infect. Dis. (2002) 34(5):563–571.
  • WALSH TJ, FINBERG RW, ARNDT C et al.: Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl. I Med. (1999) 340(10):764–771.
  • ••Seminal trial.
  • POWERS JH, DIXON CA, GOLDBERGER MJ: Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl. Med. (2002) 346(4):289–290.
  • MARR KA: Empirical antifungal therapy-new options, new tradeoffs. N Engl. I Med. (2002) 346(4):278–280.
  • SANGLARD D, ISCHERF, BILLE J. Interactions of the azole 5CH56592 with Candida albicans multidrug transporters and different cytochrome P450 forms. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (28 September-1 October 1997).
  • MARCO F, PFALLER MA, MESSER SA, JONES RN: In vitro activity of a new triazole antifungal agent, Sch 56592, against clinical isolates of filamentous fungi. Mycopathologia (1998) 141(2):73–77.
  • HACHEM R, RAAD I, AFIF C et al: An open-label, non-comparative multicenter study to evaluate the efficacy and safety of posaconazole (5CH56592) in the treatment of invasive fungal infections refractory or intolerant to standard therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (17–20 September 2000).
  • DEBONO M, GORDEE RS: Antibiotics that inhibit fungal cell wall development. Ann. Rev Microbiol (1994) 48:471–497.
  • MARCO F, PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diagn. Microbiol Infect. Dis. (1998) 32(1):33–37.
  • KURTZ MB, DOUGLAS C, MARRINAN J et al.: Increased antifungal activity of L-733,560, a water-soluble, semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob. Agents Chemother. (1994) 38(12):2750–2757.
  • PETRAITIS V, PETRAITIENE R, GROLL AH et al.: Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. (2002) 46(6):1857–1869.
  • BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2326–2332.
  • VILLANUEVA A, ARATHOON EG, GOTUZZO E, BERMAN RS, DINUBILE MJ, SABLE CA: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Gin. Infect. Dis. (2001) 33(9):1529–1535.
  • KUHN DM, GEORGE T, CHANDRA J, MUKHERJEE PK, GHANNOUM MA: Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. (2002) 46(6):1773–1780.
  • DENNING DW: Therapeutic outcome in invasive aspergillosis. Gin. Infect. Dis. (1996) 23(3):608–615.
  • REX JH, PAPPAS PG, KARCHMER AW et al. A randomized and blinded multicenter trial of high-dose fluconazole + placebo + amphotericin b as treatment of candidemia in non-neutropenic patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, Illinois, USA (16–19 December 2001)
  • POLAK A: The past, present and future of antimycotic combination therapy. Mycoses (1999) 42(5-6):355–370.
  • WILLS EA, REDINBO MR, PERFECT J, DEL POETA M: New potential targets for antifungal development. Emerg. Therap. Targets (2000) 4 (3) :1–32.
  • HECTOR RF: Compounds active against cell walls of medically important fungi. Clin. Microbiol Rev (1993) 6(1):1–21.
  • LI RK, RINALDI MG: In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole. Antimicrob. Agents Chemother. (1999) 43(6):1401–1405.
  • GEORGOPAPADAKOU NH: Antifungals targeted to sphingolipid synthesis: focus on inositol phosphorylceramide synthase. Expert Opin. Investig. Drugs (2000) 9(8):1787–1796.
  • JIANG W, GERHOLD D, KMIEC EB, HAUSER M, BECKER JM, KOLTIN Y: The topoisomerase I gene from Candida albicans. Microbiology (1997) 143\(Part 2)377–386.
  • MOLDAVE K: Eukaryotic protein synthesis. Ann. Rev Biochem. (1985) 54:1109–1149.
  • CAPA L, MENDOZA A, LAVANDERA JL, GOMEZ DE LAS HERAS F, GARCIA-BUSTOS JF: Translation elongation factor 2 is part of the target for a new family of antifungals. Antimicrob. Agents Chemother. (1998) 42 (10):2694–2699.
  • MARCHETTI O, ENTENZA JM, SANGLARD D, BILLE J, GLAUSER
  • •• MOREILLON P: Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob. Agents Chemother. (2000) 44(11):2932–2938.
  • MARCHETTI O, MOREILLON P, GLAUSER MP, BILLE J, SANGLARD D: Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother: (2000) 44(9):2373–2381.
  • CRUZ MC, GOLDSTEIN AL, BLANKENSHIP JR et al.: Calcineurin is essential for survival during membrane stress in Candida albicans. Embo. 1 (2002) 21(4):546–559.
  • STEVENS DA: Combination immunotherapy and antifungal chemotherapy. Clin. Infect. Dis. (1998) 26(6):1266–1269.
  • ••A nice review of a complicated subject.
  • POLONELLI L, CASADEVALL A, HAN Y et al.: The efficacy of acquired humoral and cellular immunity in the prevention and therapy of experimental fungal infections. Med. Mycol. (2000) 38\(Suppl. 1):281–292.
  • RENTZ AM, HALPERN MT, BOWDEN R: The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin. Infect. Dis. (1998) 27(4):781–788.
  • CAGNONI PJ, WALSH TJ, PRENDERGAST MM et al: Pharmacoeconomic analysis of fiposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. Clin. Oncol (2000) 18(12):2476–2483.
  • •Seminal pharmacoeconomics study.
  • CAGNONI PJ: Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J. Antimicrob. Chemother. (2002) 49\(Suppl. 1):81–86.
  • COOKE J: Pharmacoeconomics of antifungal therapy. Bone Marrow Transplant (1994) 14\(Suppl. 5):518–520.
  • LEWIS RE: Pharmacoeconomic analysis of antifungal therapy. Doctor Fungus (2002).
  • •See [202]. Website These websites are not referenced in the text but have been found useful by the author.

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.